Tech Company Financing Transactions
Senisca Funding Round
Senisca closed a $4.7 million funding round on 3/18/2024. Investors included APEX Ventures, Emerging Longevity Ventures and LifeSpan Vision Ventures.
Transaction Overview
Company Name
Announced On
3/18/2024
Transaction Type
Venture Equity
Amount
$4,660,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support continued evolution and the preclinical development of its senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
RILD Building Barrack Road
Exeter, EX2 5DW
UK
Exeter, EX2 5DW
UK
Phone
Website
Email Address
Overview
SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
David Chiswell
Chief Executive Officer
Sarah Cole
Chief Operating Officer
Kirsty Semple
Chief Scientific Officer
Lorna Harries
Chief Technical Officer
Ben Lee
Controller
Jessica Bennett
Vice President
Adam Clauss
VP - Bus. Development
Tim Schmidt
VP - Client Services
Tori Hammond
Browse more venture capital transactions:
Prev: 3/18/2024: Work & Mother venture capital transaction
Next: 3/18/2024: Quilt venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs